Last reviewed · How we verify
Cantharidin 0.7%
At a glance
| Generic name | Cantharidin 0.7% |
|---|---|
| Sponsor | University of North Carolina, Chapel Hill |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris) (PHASE3)
- Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2) (PHASE3)
- Investigation of the Distinct Mechanisms Involved in Inflammatory Resolution Between Healthy Men and Women (EARLY_PHASE1)
- Cantharidin and Occlusion in Verruca Epithelium (PHASE2)
- A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts (PHASE2)
- Cantharidin Application in Molluscum Patients-1 (PHASE3)
- Cantharidin Application in Molluscum Patients (PHASE3)
- Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cantharidin 0.7% CI brief — competitive landscape report
- Cantharidin 0.7% updates RSS · CI watch RSS
- University of North Carolina, Chapel Hill portfolio CI